Uric acid and long-term outcomes in CKD - Wikidata - awgldk - TriplyDB

Uric acid and long-term outcomes in CKD

Uric acid and long-term outcomes in CKD

http://www.wikidata.org/entity/Q37214752

about

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease Associations Between Hyperuricemia and Chronic Kidney Disease: A Review Uric acid and chronic kidney disease: which is chasing which?Uric acid and risk of heart failure: a systematic review and meta-analysis Urate-lowering therapy for gout: focus on febuxostat Anthropomorphic measurements that include central fat distribution are more closely related with key risk factors than BMI in CKD stage 3 Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease.Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study.Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study Association of a polymorphism in a gene encoding a urate transporter with CKD progression.Replication of the effect of SLC2A9 genetic variation on serum uric acid levels in American Indians Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients.Uric acid: a novel mediator and marker of risk in chronic kidney disease?Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study.Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus Comorbidities in patients with crystal diseases and hyperuricemia.Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002 The relationship between serum uric acid and chronic kidney disease among Appalachian adults Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease P wave dispersion and maximum P wave duration are independently associated with rapid renal function decline Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease.Serum uric acid and chronic kidney disease: the role of hypertension.Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross-sectional study.Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study.SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Uric acid as a mediator of diabetic nephropathy.Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.Vascular endothelial function is not related to serum uric acid in healthy adults.Association of Uric Acid With Vascular Stiffness in the Framingham Heart Study.Prognosis of CKD patients receiving outpatient nephrology care in Italy.EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy Hyperuricemia: A non-traditional risk factor for development and progression of chronic kidney disease?Uric acid as a target of therapy in CKD.

P2860

Q24630327-1AB50701-ADD1-4553-92B2-4FDEAB5D02AE Q26739475-2F7EFAB1-500E-4BC6-AE6C-E1909DDCA533 Q26796333-EE35091F-94F1-4516-97A0-F928D5CE8CC6 Q26824554-365F133D-F184-48AE-B9AF-2409576FE36E Q26852555-3914FF03-D2D6-4389-A07B-1003A16503EE Q28283310-BE10D0BB-AA0D-4DF6-AEF8-5AB894A0DAD1 Q28730621-E30562AF-16FE-4553-8AA1-1A3A686CB6F8 Q33611859-C83E9C5E-42A5-4AD3-97C8-796C8402B766 Q33643436-C7E3C36B-F356-46F8-B9C7-3177298C2B28 Q33706623-18F0CEAA-EFAA-4E29-805F-0EF24231ABE1 Q33715840-5432E336-CD8C-4A21-BB5B-33EE48358305 Q33765218-67945BD5-3763-4EAD-94B7-996D213E086C Q33822935-36C9BD9E-E2D3-4852-BDC4-53470707D454 Q33913892-218F8C09-A92E-4750-9DE4-7E97C6FFF28B Q33948767-3C90D8D5-0958-4084-B56C-A75CBA8CA62B Q34029265-85EFED05-24F1-450C-9799-813A50765A7F Q34085786-70FF91C3-7FA8-46FA-AFBC-D8D95012F8A2 Q34157725-AD5C43D8-0D6A-422D-B33F-811125E2175F Q34254522-23D01374-754E-4FCA-89A1-96E55A2D3BE3 Q34308220-1BABD7E2-E9E0-47D4-B7BD-FBDA4E250942 Q34317722-14CCA514-EBBA-4BB4-9762-A831DA0CA615 Q34404840-AEA6F39A-2F30-4209-B5FF-E0B73BA0B620 Q34724967-81CA5153-7547-4C53-8236-A96FAA8B0D3E Q35050256-E41CB312-644D-4205-8975-05640A533F46 Q35121532-C1737A30-E33A-4971-9740-4F6D081BF7B5 Q35134716-ECDF5CAF-0FBA-4E0B-AB47-7B2BB33F750B Q35181821-3D416899-C524-489A-8CAD-467B5B44348C Q35393446-0BD308DC-9389-4C15-BE12-262332C3E6DE Q35605560-869BC997-973B-43AC-BBE8-5E4241B0A508 Q35620128-75A9AA14-3F79-499F-B5A2-982C04388876 Q35837789-D9E5F143-F520-46F7-9A76-231F0368DC29 Q35843077-ADBE8707-B01A-460A-A48D-AAE1D6FFC1C0 Q35975531-45958AA9-EA7E-47E2-821C-85F5C50482C0 Q35985791-4FB1D9FA-0AF6-4982-9E3A-50701954A9C7 Q36223297-3B2A69B4-CEF3-4C82-917B-8CC7C033F696 Q36255567-4CAD7F22-3F28-4B02-8465-6C730C7213C7 Q36315937-6087FF8E-2B89-4DCA-8FFE-8EB2BBE4161F Q36373688-BCB0624C-F8E3-4443-B835-A3592C14C1F1 Q36471751-5A263726-ADA8-4801-B9BE-1BAE5EF33AE2 Q36476464-12B79D83-B660-4095-A21D-C2190926F994

P2860

Uric acid and long-term outcomes in CKD

http://www.wikidata.org/entity/Q37214752

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Uric acid and long-term outcomes in CKD

@en

Uric acid and long-term outcomes in CKD.

@nl

type

label

Uric acid and long-term outcomes in CKD

@en

Uric acid and long-term outcomes in CKD.

@nl

prefLabel

Uric acid and long-term outcomes in CKD

@en

Uric acid and long-term outcomes in CKD.

@nl

P1433

Q37214752-2BDAE87B-1938-46D0-96C9-AF8F8CD028BF

P1476

Q37214752-548B48D2-5A30-4FD3-BA2F-A1D0CD881BA0

P2093

Q37214752-1CC7EE83-6A36-483E-B257-6CF0771E359B

Q37214752-27601620-5D3F-4970-900D-6AFAB11351B8

Q37214752-60E4FA6D-9E85-4A62-9CAA-C32E923E0DD5

Q37214752-8439A55C-6A64-4D5A-A156-069E81DFD57B

Q37214752-9BE13373-D4DF-4A59-A34C-D3471D664463

Q37214752-B4EFCF9B-6A17-4B40-B4CE-E367932E31DF

Q37214752-DD7A9374-AFDD-4CA4-A8AA-97FE414BEB49

Q37214752-DE79040D-9C80-4CE0-972C-B3712B3F05AD

Q37214752-FCF53C7D-6084-44EF-8FB2-A3FDA6D6B037

P2860

Q37214752-0890CC61-5FCF-42E0-B776-77E5DC1FADE2

Q37214752-1D6E62B5-3E0B-4824-917D-AF88C865E518

Q37214752-21AC8A9D-00FC-4F66-BA95-E85DF2A94B2C

Q37214752-378916F5-6106-444F-A5AB-D30B0E57013D

Q37214752-4DC28F05-4F1E-4A08-8CC4-003A0173E935

Q37214752-7E554FA8-C60C-4D8E-B785-643537902080

Q37214752-9AB5AA97-198D-4263-9EE5-6C1D3DEB9BDA

Q37214752-BC6B9AB6-A789-445A-84C2-8B4E49403FE8

Q37214752-BE3C5AD1-D2ED-4F28-A27E-62F04A11C076

Q37214752-CE1FCBE9-9F6B-42B8-9A84-C7C383459CAF

P304

Q37214752-2D7BA38E-695C-4CAC-9C70-5317E4805E70

P31

Q37214752-554C5720-ED1E-4561-88B3-C7851BF44773

P356

Q37214752-7732725A-2224-43AD-8021-6C7300A5FE8B

P433

Q37214752-38F681A2-45C8-4B72-A693-2E4D1CAEA291

P478

Q37214752-746E48E8-E897-4341-A98E-BF89AB6E9A1C

P577

Q37214752-955E93B5-4A51-4E0A-B0FF-F00D2FE4CF37

P5875

Q37214752-CC73CA46-8DA1-481C-B26C-C0447EF6DF07

P698

Q37214752-D890E819-B6D2-4A02-9B0B-7F5FF607A91D

P932

Q37214752-D2930806-9E28-4351-A448-82567F14F58B

P356

J.AJKD.2008.12.021

P1433

American Journal of Kidney Diseases

P1476

Uric acid and long-term outcomes in CKD

@en

P2093

Allan J Collins

http://www.w3.org/2001/XMLSchema#string

Andrew S Levey

http://www.w3.org/2001/XMLSchema#string

Gerald J Beck

http://www.w3.org/2001/XMLSchema#string

John W Kusek

http://www.w3.org/2001/XMLSchema#string

Magdalena Madero

http://www.w3.org/2001/XMLSchema#string

Mark J Sarnak

http://www.w3.org/2001/XMLSchema#string

Tom Greene

http://www.w3.org/2001/XMLSchema#string

Vandana Menon

http://www.w3.org/2001/XMLSchema#string

Xuelei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD.

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension.

Uric acid and incident kidney disease in the community.

Serum urate and the risk of major coronary heart disease events.

Serum uric acid and hypertension: the Olivetti heart study.

Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases.

Renal outcomes of gout and hyperuricemia.

Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden.

Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes.

P304

796-803

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.AJKD.2008.12.021

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24217246

http://www.w3.org/2001/XMLSchema#string

P698

19303683

http://www.w3.org/2001/XMLSchema#string

P932

2691553

http://www.w3.org/2001/XMLSchema#string